Overview
- Temple opened paid pre‑orders at Rs 85,000 on November 1 with made‑to‑order units and shipping expected in early 2027.
- Founder Deepinder Goyal publicly defended the product in early November, saying Temple has cost about $30 million to develop with $20 million of his personal funds and highlighting a 14‑day no‑questions return policy.
- Several doctors have challenged Temple's core claim that a forehead sensor over the superficial temporal artery measures intracranial cerebral blood flow, arguing the sensor likely reads superficial scalp circulation and not brain circulation.
- Temple and Goyal position the product as a wellness and fitness device rather than a regulated medical device and have promised pre‑prints and independent studies as the company moves toward broader validation.
- The dispute raises reputational and regulatory risk as Temple scales rapidly with major seed funding and acquisitions, and it could produce wider scrutiny of how consumer wearables are validated before clinical use or medical claims are made.